Current Report Filing (8-k)
August 11 2020 - 6:55AM
Edgar (US Regulatory)
0001006281
false
0001006281
2020-08-11
2020-08-11
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event
Reported): August 11, 2020
Protalix BioTherapeutics, Inc.
(Exact name of registrant as specified
in its charter)
Delaware
|
|
001-33357
|
|
65-0643773
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
2 Snunit Street
|
|
|
Science Park, POB 455
|
|
|
Carmiel, Israel
|
|
2161401
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code +972-4-988-9488
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written
communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common stock, $0.001 par value
|
PLX
|
NYSE American
|
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth
company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
On August 11, 2020, Protalix BioTherapeutics, Inc., a Delaware
corporation (the “Company”), issued a press release, together with its development and commercialization partner, Chiesi
Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A. (“Chiesi”), announcing that the U.S. Food and Drug
Administration (FDA) has accepted the Biologics License Application (BLA) and granted Priority Review designation for pegunigalsidase
alfa for the proposed treatment of adult patients with Fabry disease. Pegunigalsidase alfa is the Company’s purposefully-designed,
long-acting recombinant, PEGylated, cross-linked α-galactosidase-A investigational product candidate. A copy of the press
release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 11, 2020
|
PROTALIX BIOTHERAPEUTICS, INC.
|
|
|
|
By:
|
/s/ Dror Bashan
|
|
|
Name: Dror Bashan
|
|
|
Title: President and Chief Executive Officer
|
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Sep 2023 to Sep 2024